These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 9520115)

  • 41. [Coronary heart disease and lipoprotein (a): relationship with other lipid cardiovascular risk factors].
    Nogués X; Sentí M; Pedro-Botet J; Molina L; Serrat R; Pons S; Rubiés-Prat J
    Med Clin (Barc); 1992 Feb; 98(5):171-4. PubMed ID: 1532436
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Plasma lipoprotein(a) predicts major cardiovascular events in patients with chronic kidney disease who undergo percutaneous coronary intervention.
    Konishi H; Miyauchi K; Tsuboi S; Ogita M; Naito R; Dohi T; Kasai T; Tamura H; Okazaki S; Isoda K; Daida H
    Int J Cardiol; 2016 Feb; 205():50-53. PubMed ID: 26710333
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lipoprotein(a)-cholesterol and coronary heart disease in the Framingham Heart Study.
    Seman LJ; DeLuca C; Jenner JL; Cupples LA; McNamara JR; Wilson PW; Castelli WP; Ordovas JM; Schaefer EJ
    Clin Chem; 1999 Jul; 45(7):1039-46. PubMed ID: 10388480
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lp(a) lipoprotein is a major risk factor for cardiovascular disease: pathogenic mechanisms and clinical significance.
    Dahlén GH; Stenlund H
    Clin Genet; 1997 Nov; 52(5):272-80. PubMed ID: 9520117
    [TBL] [Abstract][Full Text] [Related]  

  • 45. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease.
    Baigent C; Landray M; Leaper C; Altmann P; Armitage J; Baxter A; Cairns HS; Collins R; Foley RN; Frighi V; Kourellias K; Ratcliffe PJ; Rogerson M; Scoble JE; Tomson CR; Warwick G; Wheeler DC
    Am J Kidney Dis; 2005 Mar; 45(3):473-84. PubMed ID: 15754269
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lipoprotein(a) as a risk factor for coronary artery disease in hemodialysis patients.
    Ohashi H; Oda H; Ohno M; Watanabe S; Sakata S
    Kidney Int Suppl; 1999 Jul; 71():S242-4. PubMed ID: 10412788
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk.
    von Eckardstein A; Schulte H; Cullen P; Assmann G
    J Am Coll Cardiol; 2001 Feb; 37(2):434-9. PubMed ID: 11216959
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease.
    Tsimikas S; Brilakis ES; Miller ER; McConnell JP; Lennon RJ; Kornman KS; Witztum JL; Berger PB
    N Engl J Med; 2005 Jul; 353(1):46-57. PubMed ID: 16000355
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Association of lipoprotein(a) level with short- and long-term outcomes after CABG: The role of lipoprotein apheresis.
    Ezhov MV; Afanasieva OI; Il'ina LN; Safarova MS; Adamova IY; Matchin YG; Konovalov GA; Akchurin RS; Pokrovsky SN
    Atheroscler Suppl; 2017 Nov; 30():187-192. PubMed ID: 29096836
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Association of fibrinogen and lipoprotein(a) as a coronary heart disease risk factor in men (The Quebec Cardiovascular Study).
    Cantin B; Després JP; Lamarche B; Moorjani S; Lupien PJ; Bogaty P; Bergeron J; Dagenais GR
    Am J Cardiol; 2002 Mar; 89(6):662-6. PubMed ID: 11897206
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults ≥65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study).
    Foody JM; Brown WV; Zieve F; Adewale AJ; Flaim D; Lowe RS; Jones-Burton C; Tershakovec AM
    Am J Cardiol; 2010 Nov; 106(9):1255-63. PubMed ID: 21029821
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events.
    Grover SA; Coupal L; Paquet S; Zowall H
    Arch Intern Med; 1999 Mar; 159(6):593-600. PubMed ID: 10090116
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lipoprotein (a) in patients with psoriasis: associations with lipid profiles and disease severity.
    Pietrzak A; Kadzielewski J; Janowski K; Roliński J; Krasowska D; Chodorowska G; Paszkowski T; Kapeć E; Jastrzebska I; Tabarkiewicz J; Lotti T
    Int J Dermatol; 2009 Apr; 48(4):379-87. PubMed ID: 19335423
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Is an elevated level of serum lipoprotein (a) a risk factor for cardiovascular disease in CAPD patients?
    Avram MM; Sreedhara R; Patel N; Chattopadhyay J; Thu T; Fein P
    Adv Perit Dial; 1996; 12():266-71. PubMed ID: 8865917
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Simvastatin but not bezafibrate decreases plasma lipoprotein-associated phospholipase A₂ mass in type 2 diabetes mellitus: relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity.
    Constantinides A; de Vries R; van Leeuwen JJ; Gautier T; van Pelt LJ; Tselepis AD; Lagrost L; Dullaart RP
    Eur J Intern Med; 2012 Oct; 23(7):633-8. PubMed ID: 22902096
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study.
    Leebmann J; Roeseler E; Julius U; Heigl F; Spitthoever R; Heutling D; Breitenberger P; Maerz W; Lehmacher W; Heibges A; Klingel R;
    Circulation; 2013 Dec; 128(24):2567-76. PubMed ID: 24056686
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lipids and Lp(a) lipoprotein levels and coronary artery disease in subjects with non-insulin-dependent diabetes mellitus.
    O'Brien T; Nguyen TT; Harrison JM; Bailey KR; Dyck PJ; Kottke BA
    Mayo Clin Proc; 1994 May; 69(5):430-5. PubMed ID: 8170193
    [TBL] [Abstract][Full Text] [Related]  

  • 58. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.
    Pedersen TR; Faergeman O; Kastelein JJ; Olsson AG; Tikkanen MJ; Holme I; Larsen ML; Bendiksen FS; Lindahl C; Szarek M; Tsai J;
    JAMA; 2005 Nov; 294(19):2437-45. PubMed ID: 16287954
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk.
    Arsenault BJ; Petrides F; Tabet F; Bao W; Hovingh GK; Boekholdt SM; Ramin-Mangata S; Meilhac O; DeMicco D; Rye KA; Waters DD; Kastelein JJP; Barter P; Lambert G
    J Clin Lipidol; 2018; 12(1):130-136. PubMed ID: 29103916
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of simvastatin on Lp(a) concentrations.
    Haffner S; Orchard T; Stein E; Schmidt D; LaBelle P
    Clin Cardiol; 1995 May; 18(5):261-7. PubMed ID: 7628131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.